Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II alternating FOLFIRI plus bevacizumab and oxaliplatin-based hepatic arterial infusion plus de Gramont regimen and bevacizumab for unresectable colorectal liver metastases
2007-003484-45Phase 2Active
- Sponsor
- Istituto Oncologico Veneto
- Start
- Jun 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, irinotecan, oxaliplatin, fluorouracil and levoleucovorin in colorectal cancer (CRC), sponsored by Istituto Oncologico Veneto. Primary endpoint: Tumor response rate. Started Jun 2007; status: active.
02
Drugs
bevacizumabirinotecanoxaliplatinfluorouracillevoleucovorin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-003484-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003484-45.